Q4 2024 Biofrontera Inc Earnings Call Transcript
Key Points
- Biofrontera Inc (BFRI) achieved record sales of $37.3 million in 2024, marking an annual sales growth of 18.5% for Q4 and nearly 10% for the entire year.
- The company successfully placed 100 XL lamps between June 2024 and the end of the year, enhancing their photodynamic therapy (PDT) offerings.
- FDA approval was obtained to use up to 3 tubes of Ameluz per treatment, expanding treatment capabilities for actinic keratosis.
- Significant results were achieved in a phase 3 study for Ameluz's photodynamic therapy in treating superficial basal cell carcinoma.
- Biofrontera Inc (BFRI) renegotiated agreements with its former parent company, reducing the transfer price of Ameluz from 50% to 25%, positively impacting cost of goods sold.
- Despite record sales, Biofrontera Inc (BFRI) reported a net loss of $1.4 million for Q4 2024, compared to a net income of $3.5 million in the prior year quarter.
- The company's adjusted EBITDA for the full year 2024 was negative $15.3 million, though improved from negative $19.5 million in 2023.
- Operating expenses remained high at $54.5 million for 2024, although slightly reduced from $56.7 million in 2023.
- The net loss for the full year 2024 was $17.8 million, indicating ongoing financial challenges.
- Biofrontera Inc (BFRI) faces uncertainties and risks associated with its business, as highlighted by management's caution on forward-looking statements.
Good morning and welcome to the Biofrontera fourth quarter in fiscal 2024 Financial results and Business update conference call. (Operator Instructions) I would now like to turn the conference over to Andrew Barwicki, investor relations representative. Please go ahead.
Thank you. Good morning and welcome to Biofrontera Incorporate's fourth quarter in fiscal year 2024 financial results and business update conference call.
Actual results may differ materially. Please note that certain information discussed during today's call by management is covered under the safe harbour provisions of the Private Securities Litigation Reform Act. We caution listeners that Biofrontera's management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to risk. And uncertainties associated with the company's business.
All risks and uncertainties are detailed in and are qualified by the cautionary statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
